Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate vaccine (PCV) candidate, VAX-31 with the first subjects now dosed in this ...

The company is also developing a 24-valent pneumococcal vaccine, VAX-24, which is in a phase 2 study in paediatric patients, with results due in the first quarter of 2025.

During the period, seven children were supposed to have received the hepatitis B vaccine. But the records showed two doses were unused, while two extra shots of the 15-valent pneumococcal ...

A phase 3 trial of a 23-valent pneumococcal disease vaccine candidate is the biggest anticipated outlay in the non-core pipeline. Ab&B plans to start the study around the end of the year.

2 controlled studies in South Africa evaluated ... meningococcal polysaccharide serogroup A or placebo. The 6- and 12-valent vaccines achieved a protective efficacy of 76% and 92%, respectively ...